Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

Clinical trial NCT06841172 · RECRUITING

Trial details

NCT number: NCT06841172
Sponsor: Shandong Cancer Hospital and Institute
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

OligoProgressive Metastatic Disease Hepatocellular Carcinoma (HCC)Radiotherapy Systemic Therapy

Start date: 2025-07-21
Primary completion: 2027-07-01
Enrollment: 132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.